Joint Laboratories International Inc.: Received a milestone payment of $9 million from Novo Nordisk for UBT251's global phase II clinical trial.

Zhitongcaijing · 1d ago
Joint Laboratories International Inc.: Received a milestone payment of $9 million from Novo Nordisk for UBT251's global phase II clinical trial.